Arbutus Biopharma Corporation (ABUS) Options Greeks
Options Greeks measure sensitivity to various factors: Delta (price), Gamma (delta change), Theta (time decay), and Vega (volatility). They are essential for risk management and position sizing.
Arbutus Biopharma Corporation (ABUS) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $848.8M, listed on NASDAQ, employing roughly 44 people, carrying a beta of 0.62 to the broader market. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Led by Lindsay Androski, public since 2007-07-26.
Snapshot as of May 15, 2026.
- Spot Price
- $4.25
- Net Gamma
- -$14.0K
- Net Delta
- $75.1K
- Net Vega
- -$9.2K
- ATM IV
- 405.2%
- Gamma Concentration
- 0.45
As of May 15, 2026, Arbutus Biopharma Corporation (ABUS) aggregate Greeks are net delta $75.1K, net gamma -$14.0K, net vega -$9.2K, ATM IV 405.2%. Gamma concentration is 0.45: gamma is more dispersed, reducing any single-strike pinning force. Delta measures directional exposure, gamma measures the rate of delta change, and vega measures sensitivity to implied volatility. Net aggregate Greeks summarize the total dealer book across all strikes and expirations.
How ABUS options greeks Data Feeds Strategy Selection
Strategy selection on Arbutus Biopharma Corporation options does not derive from any single metric in isolation. The options greeks view above sits inside a broader read: ATM IV currently sits at 405.2% and dealer gamma exposure is negative, so dealer hedging amplifies directional moves. Combine the options greeks data here with the volatility-skew surface, dealer-gamma exposure, max-pain level, and upcoming-events calendar to build a positioning thesis. Risk-defined structures (credit spreads, debit spreads, iron condors) are usually safer than naked positions while the regime is uncertain; the data on this page anchors the inputs but does not by itself constitute a trade thesis.
Learn how options Greeks is reported and how to read the data →
Frequently asked ABUS options greeks questions
- What are the ABUS aggregate Greek exposures?
- As of May 15, 2026, Arbutus Biopharma Corporation (ABUS) snapshot Greeks are net delta $75.1K, net gamma -$14.0K, net vega -$9.2K. These aggregate the dealer book across all listed strikes and expirations under the standard customer-versus-dealer sign convention.
- What does the ABUS net dealer delta tell us?
- Net dealer delta of $75.1K represents the directional exposure dealers carry from their option inventory. Dealers continuously hedge this exposure with stock, futures, or correlated instruments, so the size of net delta is also the size of hedge flow that will execute as spot moves.
- How do ABUS Greeks inform hedging?
- Delta tracks first-order directional exposure; gamma tracks how quickly delta changes; vega tracks IV sensitivity. Aggregated dealer Greeks let traders read the dealer-positioning regime: long-gamma regimes mean-revert moves; short-gamma regimes amplify them. Vega exposure indicates how dealer P&L responds to vol shocks and hence the direction of vol-shock hedging flows.